Edwards Lifesciences (EW) Liabilities and Shareholders Equity (2009 - 2026)

Edwards Lifesciences' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $13.3 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 2.3% year-over-year to $13.3 billion; the TTM figure through Mar 2026 stood at $53.8 billion (up 9.42% YoY), while the FY2025 annual figure was $13.7 billion, up 4.92% from the prior year.
• Liabilities and Shareholders Equity was $13.3 billion for Q1 2026 at Edwards Lifesciences, down from $13.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $13.7 billion in Q4 2025 to a low of $8.3 billion in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $10.8 billion across 5 years, with a median of $9.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity retreated 2.47% in 2022, then soared 39.43% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $8.3 billion in 2022, then gained by 12.91% to $9.4 billion in 2023, then jumped by 39.43% to $13.1 billion in 2024, then grew by 4.92% to $13.7 billion in 2025, then declined by 2.75% to $13.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $13.3 billion (Q1 2026), $13.7 billion (Q4 2025), and $13.3 billion (Q3 2025), per Business Quant data.